NCT04217837View on ClinicalTrials.gov

Treatment of Major Depressive Disorder in the UK Using TMS Therapy

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

March 31, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Major Depressive Disorder
Interventions
DEVICE

Transcranial Magnetic Stimulator

Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.

Trial Locations (1)

NW1 0PE

St Pancras Hospital, London

Sponsors

Lead Sponsor

Neuronetics
All Listed Sponsors
lead

Neuronetics

OTHER

NCT04217837 - Treatment of Major Depressive Disorder in the UK Using TMS Therapy | Biotech Hunter | Biotech Hunter